Showing results (111-120 of 196) with videos related to
Sort By:
Pageof 20
Ophthalmology Science|October 17, 2022
Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in RetinoblastomaDavid H Abramson, Diana Mandelker, Jasmine H Francis, et al.JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic ApproachJason C Chang, Deepu Alex, Matthew Bott, et al.The Journal of Molecular Diagnostics : JMD|December 7, 2020
A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic SequencingSounak Gupta, Chad M Vanderbilt, Yun-Te Lin, et al.The Journal of Molecular Diagnostics : JMD|June 17, 2023
Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR TechnologyMaria E Arcila, Utsav Patel, Amir Momeni-Boroujeni, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapiesAlan P Venook, Maria E Arcila, Al B Benson, et al.Plos One|February 3, 2023
Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot studyDavid H Abramson, Diana L Mandelker, A Rose Brannon, et al.Blood Advances|December 12, 2018
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiationWenbin Xiao, Maheetha Bharadwaj, Max Levine, et al.JAMA Oncology|May 29, 2020
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label TrialHelena A Yu, Adam J Schoenfeld, Alex Makhnin, et al.Acta Neuropathologica Communications|November 10, 2020
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusionsDouglas A Mata, Jamal K Benhamida, Andrew L Lin, et al.Pageof 20